

the other drug. The two aliphatic derivatives, chlorpromazine and triflupromazine, produced more reactions than the piperidine derivative, mepazine, or phenobarbital.

Table II indicates the number of patients showing any abnormal symptom in each of the drug treatment groups. The median daily dose at which drowsiness was produced varied considerably (prochlorperazine, 35 mg.; perphenazine, 48 mg.; triflupromazine, 60 mg.; mepazine, 75 mg.;

phenobarbital, 96 mg.; chlorpromazine, 200 mg.). The majority of adverse behavioral effects appeared during the first 3 weeks of treatment; their persistence was comparable for each of the drugs. Mental depression and "turbulence" (anxiety and agitation), usually considered adverse effects of phenothiazine derivatives, were equally common with phenobarbital.

Extrapyramidal effects were more frequent from the piperazinylphenothiazines

Table II. Number of patients in each drug group showing clinically observed side effects

Symptom or sign	Total N = 599	Pheno- barbital 99	Prochlor- perazine 100	Triflupro- mazine 96	Mepazine 103	Prochlor- perazine 100	Perphena- zine 101
<i>Adverse behavior</i>							
Drowsiness	232	28	48	38	28	44	46
Depression	103	18	15	13	15	23	19
Anxiety	198	38	29	26	28	41	36
Agitation	181	44	20	26	30	27	34
<i>Central nervous system</i>							
Extrapyramidal effects	52	0	8	6	2	15	21
Impaired associated movements	57	2	8	10	1	16	20
Rigidity	62	0	9	9	2	15	27
Tremor	47	2	10	5	5	10	15
Akathisia	110	12	16	16	12	20	34
Dystonia (spasm)	16	1	2	3	1	3	6
Weakness, fatigue	135	16	28	18	16	29	28
Seizures	4	0	0	1	1	1	1
<i>Autonomic nervous system</i>							
Fainting	16	2	4	1	2	4	3
Blurred vision	90	10	16	8	24	14	18
Nausea, vomiting	60	6	13	10	5	17	9
Dryness of mouth	107	13	20	11	24	20	19
Constipation	89	10	17	14	23	12	13
<i>Allergic effects</i>							
Dermatitis	21	3	7	4	2	4	1

Table III. Changes in leukocyte and eosinophil counts during 12 week treatment period

Drug	Eosinophilia		Leukocytosis		Leukopenia	
	No. of patients	Total No. counts	No. of patients	Total No. counts	No. of patients	Total No. counts
Phenobarbital	20 (4)*	40	16 (3)	40	9 (5)	19
Chlorpromazine	18 (3)	34	12 (2)	13	7 (6)	23
Triflupromazine	11 (0)	22	11 (3)	32	3 (3)	4
Mepazine	17 (4)	37	12 (4)	25	8 (5)	29
Prochlorperazine	16 (1)	42	19 (1)	42	2 (3)	5
Perphenazine	16 (4)	31	16 (2)	33	7 (4)	14

*Numbers in parentheses indicate patients with abnormal control values.